How to get retatrutide prescribed

Getting retatrutide right now is not as simple as asking your doctor for a prescription. As of April 2026, retatrutide is still an investigational drug in Phase 3 clinical trials, which means it has not received FDA approval and is not available through standard pharmacy channels. That does not mean access is impossible, but it does limit your options significantly compared to FDA-approved medications like tirzepatide.

Here is what you need to know about every current pathway to retatrutide, what the timeline looks like for broader availability, and how to position yourself for access as soon as it becomes prescribable.

Key takeaways

• Retatrutide is not FDA approved and cannot be prescribed through normal channels as of April 2026
• Clinical trial enrollment is the primary legal access route right now
• Some compounding pharmacies may offer retatrutide under physician supervision, though regulatory status is gray
• Eli Lilly expects to complete Phase 3 trials in late 2026, with a possible FDA submission in 2027
• Telehealth platforms will likely offer retatrutide prescriptions once FDA approval is granted
• Approved alternatives like tirzepatide and semaglutide are available now for weight loss

Why you cannot get a standard retatrutide prescription yet

The FDA requires drugs to complete Phase 3 clinical trials and receive formal approval before doctors can write prescriptions filled at retail pharmacies. Retatrutide (LY3437943) is Eli Lilly’s investigational triple-receptor agonist that targets GIP, GLP-1, and glucagon receptors simultaneously [1]. The Phase 2 trial published in the New England Journal of Medicine showed 24.2% body weight reduction at the highest dose over 48 weeks [2]. Those results were strong enough to launch the TRIUMPH Phase 3 program.

The first Phase 3 results from TRIUMPH-4 came in December 2025, showing 28.7% weight loss at the 12 mg dose over 68 weeks [3]. Seven more Phase 3 trials are expected to complete in 2026 [3]. But until Eli Lilly submits a New Drug Application and the FDA reviews it, retatrutide remains off-limits for standard prescribing.

This is different from older peptides that exist in regulatory gray areas. Retatrutide is a novel molecule owned by a major pharmaceutical company actively pursuing FDA approval. There is no generic version, no compounding loophole like those used for semaglutide, and no research chemical supply chain.

Current ways to access retatrutide

Clinical trial enrollment

The most straightforward legal path to retatrutide is enrolling in one of Eli Lilly’s active clinical trials. The TRIUMPH program includes trials for several conditions:

• Obesity and overweight (TRIUMPH-1, TRIUMPH-3)
• Type 2 diabetes (TRIUMPH-2)
• Obesity with knee osteoarthritis (TRIUMPH-4, completed)
• Obstructive sleep apnea
• Chronic low back pain
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Cardiovascular and renal outcomes

You can search for active retatrutide trials at ClinicalTrials.gov using the identifier LY3437943. Eligibility typically requires a BMI of 27 kg/m² or higher with at least one weight-related condition, or a BMI of 30 kg/m² or higher without additional conditions [3].

The catch: clinical trials are randomized and placebo-controlled. You may receive placebo instead of the active drug. You also need to meet specific inclusion criteria and commit to regular study visits, blood work, and monitoring for the trial duration (typically 48 to 72 weeks).

Compounding pharmacy access

Some compounding pharmacies have begun sourcing retatrutide raw material and preparing it under physician orders. This exists in a regulatory gray area. Unlike semaglutide, which has an established compounding pathway under FDA shortage provisions, retatrutide does not have the same legal framework for compounding.

If you pursue this route, verify that the pharmacy is a 503A or 503B registered facility. A 503B outsourcing facility provides more oversight and testing. Your prescribing physician takes on significant liability when ordering a non-approved compound, so expect thorough medical screening before any provider agrees to this.

Costs through compounding pharmacies vary widely. Without insurance coverage or manufacturer pricing, expect to pay several hundred dollars per month. This pricing may change as the market develops.

Research chemical suppliers

Some peptide research companies sell retatrutide labeled “for research purposes only.” These products are not intended for human use, are not manufactured under pharmaceutical-grade conditions, and carry real safety risks. Purity testing is inconsistent, and you have no recourse if the product is contaminated or misdosed.

We do not recommend this route. The difference between research peptides and prescription peptides is not just legal semantics. It is a matter of manufacturing standards, purity verification, and medical oversight.

What to do while waiting for FDA approval

The timeline for FDA approval of retatrutide is likely 2027 or 2028, depending on how quickly Phase 3 data is compiled and reviewed. That is a long wait if you need weight management help now. Several proven alternatives are available today through telehealth platforms and online prescriptions.

Tirzepatide (Mounjaro/Zepbound)

Tirzepatide is the closest available medication to retatrutide. It targets two of the same three receptors (GIP and GLP-1) and has shown weight loss of up to 22.5% in clinical trials [4]. It is FDA-approved for both type 2 diabetes (as Mounjaro) and obesity (as Zepbound). You can get a tirzepatide prescription online today through telehealth providers.

Semaglutide (Ozempic/Wegovy)

Semaglutide targets GLP-1 receptors alone and has shown weight loss of approximately 15% in the STEP trials [5]. It is widely available, including through compounded versions that cost less than brand-name options. An online semaglutide prescription is one of the most accessible weight loss medication options right now.

Other peptide options

For patients interested in the broader peptide therapy space, options like sermorelin for growth hormone optimization or peptide stacks for fat loss may provide complementary benefits while you wait for retatrutide availability.

Understanding the prescription process for weight loss medications

If you have never been prescribed a weight loss medication before, here is how the process works for currently available drugs like tirzepatide and semaglutide. The retatrutide prescription process will almost certainly follow the same pattern.

Your provider evaluates several factors before prescribing: your current BMI, weight history, prior weight loss attempts (diet, exercise, other medications), lab work (metabolic panel, A1C, liver enzymes, thyroid function), and existing medications that might interact. They also screen for contraindications specific to GLP-1 class drugs, including personal or family history of medullary thyroid carcinoma and pancreatitis history.

The evaluation can happen in person or through a telehealth consultation. For GLP-1 medications, telehealth has become the dominant access method. Most platforms accept patients from all 50 states, though prescribing regulations vary by state. The growth of telehealth prescribing for weight loss medications has made access significantly easier compared to even a few years ago. See can telehealth prescribe peptides for more on how this works.

Once prescribed, the medication is sent from a licensed pharmacy (either retail or compounding) directly to your home. You receive injection supplies, dosing instructions, and access to provider support for questions during treatment.

How telehealth will work once retatrutide is approved

Based on how tirzepatide and semaglutide prescribing works today, here is what the retatrutide prescription process will likely look like after FDA approval:

1. Complete an online health questionnaire covering your weight history, BMI, medical conditions, and current medications
2. Have a video or phone consultation with a licensed provider who reviews your information and determines if you are a candidate
3. If approved, your provider sends the prescription to a pharmacy
4. The medication ships directly to your home with injection supplies and instructions

The entire process from initial consultation to receiving medication typically takes 3 to 7 days with current telehealth platforms.

Retatrutide will be a once-weekly subcutaneous injection, similar to tirzepatide and semaglutide. If you have never injected before, read our guide on how to inject peptides to familiarize yourself with the process. It uses a small needle and takes about 30 seconds.

Qualifying for retatrutide

Based on the Phase 3 trial criteria and typical FDA weight loss medication approvals, you will likely qualify for retatrutide if you meet one of these profiles:

• BMI of 30 or higher (obesity) regardless of other conditions
• BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea
• BMI of 27 or higher with knee osteoarthritis (a specific indication being tested in TRIUMPH-4)

Your provider will also screen for contraindications. Based on trial exclusion criteria, retatrutide may not be appropriate if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pancreatitis [2].

Step-by-step: positioning yourself for retatrutide access

While you cannot walk into a pharmacy and fill a retatrutide prescription today, there are concrete steps you can take now to be ready when it becomes available.

Step 1: Establish care with a weight-loss focused provider. Find a physician or telehealth platform that prescribes GLP-1 medications. Providers who already prescribe tirzepatide and semaglutide will be first to add retatrutide when it launches.

Step 2: Document your weight history. Insurance coverage decisions often depend on documented medical necessity. Start building a paper trail now: BMI measurements, lab work showing metabolic markers, records of prior weight loss attempts, and any comorbidities like sleep apnea, hypertension, or type 2 diabetes.

Step 3: Try current options first. Starting with semaglutide or tirzepatide now does two things. First, you begin losing weight immediately instead of waiting 1-2 years. Second, having tried existing treatments strengthens the case for a newer medication if you later need to switch to retatrutide for better results.

Step 4: Monitor trial enrollment. Set up alerts on ClinicalTrials.gov for new retatrutide studies. Enrollment criteria, site locations, and availability change as trials progress.

Step 5: Stay informed on FDA timelines. The retatrutide FDA approval timeline will shift as data comes in. Following Eli Lilly’s investor relations page and the FDA’s calendar gives you the earliest heads-up when things move forward.

Expected cost of retatrutide

Eli Lilly has not announced pricing for retatrutide. Based on comparable products:

• Tirzepatide (Zepbound) carries a list price of approximately $1,060 per month without insurance
• Semaglutide (Wegovy) is approximately $1,350 per month without insurance
• Compounded versions of these medications range from $200 to $500 per month

Retatrutide, as a novel triple agonist, may be priced at a premium to existing dual agonists. Insurance coverage will depend on FDA-approved indications and individual plan formularies. For context on peptide therapy costs, our pricing guide breaks down what to expect across different medications.

Frequently asked questions

Can my doctor prescribe retatrutide right now?▼

No. As of April 2026, retatrutide has not received FDA approval and cannot be prescribed through standard channels. Some physicians may prescribe it through compounding pharmacies, but this is not the same as a standard FDA-approved prescription and carries additional risks.

When will retatrutide be available by prescription?▼

The most likely timeline is 2027 or 2028. Eli Lilly needs to complete its Phase 3 TRIUMPH program (seven remaining trials expected in 2026), compile the data, and submit a New Drug Application to the FDA. The FDA review process typically takes 10 to 12 months after submission.

Is retatrutide available through compounding pharmacies?▼

Some compounding pharmacies have begun offering retatrutide preparations. This exists in a regulatory gray area because retatrutide is not an FDA-approved drug with an established compounding pathway. If you go this route, insist on a 503B outsourcing facility and full certificate of analysis testing.

What is the best alternative to retatrutide available now?▼

Tirzepatide is the closest FDA-approved alternative. It shares two of three receptor targets with retatrutide (GIP and GLP-1) and has shown weight loss of up to 22.5% in clinical trials. The main difference is that retatrutide also targets glucagon receptors, which may contribute to additional fat burning and metabolic benefits.

How much will retatrutide cost when it is available?▼

Pricing has not been announced. Expect it to be comparable to or higher than tirzepatide (Zepbound), which lists at approximately $1,060 per month. Compounded versions may become available at lower prices depending on patent and exclusivity status. See our retatrutide cost guide for updated pricing information.

Can I enroll in a retatrutide clinical trial?▼

Yes, if you meet the eligibility criteria. Search ClinicalTrials.gov for “retatrutide” or “LY3437943” to find active enrollment sites near you. Be aware that trials are randomized, meaning you may receive placebo instead of the active drug.

Will insurance cover retatrutide?▼

That depends on the approved indications and your insurance plan. If FDA-approved for obesity, coverage will likely mirror current GLP-1 medication policies. Many plans now cover tirzepatide for weight loss. Check our guide on insurance coverage for peptide therapy for more details.

References

1. Eli Lilly and Company. Retatrutide (LY3437943) investigational drug profile. ClinicalTrials.gov.
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
3. Eli Lilly. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Press release. December 11, 2025.
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.